IRIS
CASCINU, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.355
EU - Europa 7.737
AS - Asia 6.292
SA - Sud America 2.177
AF - Africa 358
Continente sconosciuto - Info sul continente non disponibili 14
OC - Oceania 6
Totale 30.939
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.171
SG - Singapore 1.931
RU - Federazione Russa 1.902
BR - Brasile 1.724
VN - Vietnam 1.461
UA - Ucraina 1.382
CN - Cina 728
IE - Irlanda 695
DE - Germania 690
TR - Turchia 640
IT - Italia 628
SE - Svezia 627
HK - Hong Kong 558
DK - Danimarca 542
FR - Francia 443
FI - Finlandia 391
KR - Corea 286
GB - Regno Unito 229
AR - Argentina 156
IN - India 134
CI - Costa d'Avorio 124
BD - Bangladesh 110
EC - Ecuador 82
IQ - Iraq 82
ID - Indonesia 80
MX - Messico 72
MA - Marocco 66
ZA - Sudafrica 62
CO - Colombia 59
CA - Canada 56
VE - Venezuela 43
JP - Giappone 41
NL - Olanda 41
CL - Cile 39
PK - Pakistan 33
BE - Belgio 31
PH - Filippine 30
PL - Polonia 28
UZ - Uzbekistan 28
PY - Paraguay 27
ES - Italia 25
KE - Kenya 22
DZ - Algeria 21
MY - Malesia 20
PE - Perù 20
TN - Tunisia 20
UY - Uruguay 19
EG - Egitto 18
SA - Arabia Saudita 18
AE - Emirati Arabi Uniti 12
RO - Romania 12
DO - Repubblica Dominicana 11
EU - Europa 11
AL - Albania 10
AZ - Azerbaigian 10
AT - Austria 9
CR - Costa Rica 9
KZ - Kazakistan 9
HN - Honduras 8
JO - Giordania 8
BG - Bulgaria 7
IL - Israele 7
LT - Lituania 7
NP - Nepal 7
OM - Oman 7
PA - Panama 7
RS - Serbia 7
BH - Bahrain 6
LB - Libano 6
TH - Thailandia 6
CZ - Repubblica Ceca 5
ET - Etiopia 5
JM - Giamaica 5
KG - Kirghizistan 5
NI - Nicaragua 5
GY - Guiana 4
MD - Moldavia 4
PS - Palestinian Territory 4
QA - Qatar 4
TW - Taiwan 4
AU - Australia 3
BA - Bosnia-Erzegovina 3
CH - Svizzera 3
GE - Georgia 3
GR - Grecia 3
IR - Iran 3
KW - Kuwait 3
LY - Libia 3
NG - Nigeria 3
PR - Porto Rico 3
SC - Seychelles 3
SN - Senegal 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
AO - Angola 2
BO - Bolivia 2
BS - Bahamas 2
EE - Estonia 2
MR - Mauritania 2
Totale 30.910
Salva come PNG Salva come JPEG
Città #
Ashburn 2.268
Dallas 1.916
Jacksonville 1.394
Singapore 1.145
Fairfield 1.025
Chandler 755
Dublin 693
Boardman 670
Wilmington 551
Hong Kong 541
Ho Chi Minh City 447
Woodbridge 423
Houston 392
San Jose 372
Seattle 371
Hanoi 333
The Dalles 323
New York 312
San Mateo 281
Lawrence 279
Princeton 279
Cambridge 272
Moscow 237
Lauterbourg 236
Ann Arbor 220
Centro 206
Beijing 190
Los Angeles 163
Des Moines 161
Hefei 149
São Paulo 146
Abidjan 123
San Diego 123
Helsinki 73
Munich 73
Da Nang 72
Buffalo 67
Haiphong 62
Rio de Janeiro 53
London 52
Orem 49
Turin 48
Chicago 44
Turku 41
Porto Alegre 37
Brasília 36
Santa Clara 35
Belo Horizonte 34
Tokyo 34
Guayaquil 31
Biên Hòa 30
Milan 30
Frankfurt am Main 29
Hải Dương 29
Chennai 28
Johannesburg 28
Montreal 28
Baghdad 27
Stockholm 26
Brussels 25
Curitiba 25
Tashkent 25
Warsaw 24
Ninh Bình 23
Campinas 22
Marche 22
Norwalk 22
Quito 22
Thái Bình 22
Fortaleza 21
Manchester 21
Dhaka 20
Kilburn 20
Nairobi 20
Rome 20
Santiago 20
Brooklyn 19
Denver 19
Guangzhou 19
Bogotá 17
Can Tho 17
Council Bluffs 17
Montevideo 17
Mumbai 17
Pune 17
Shanghai 17
Boston 16
Guarulhos 16
Izmir 16
Washington 16
Amsterdam 15
Lima 15
Cape Town 14
Casablanca 14
Phoenix 14
Poplar 14
Salvador 14
San Francisco 14
Thái Nguyên 14
Ankara 13
Totale 18.847
Salva come PNG Salva come JPEG
Nome #
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 2.280
Anemia may influence the outcome of patients undergoing neoadjuvant treatment for rectal cancer 212
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. 198
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment 193
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: A multicentric retrospective analysis 187
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies 185
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. 181
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. 178
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 174
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. 174
A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. 173
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 173
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in Renal Cell Carcinoma 170
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 169
A cost-benefit analysis of chemotherapy for gastric cancer. 165
KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma 164
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 164
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. 164
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 160
Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy. 157
Neutrophil‑to‑lymphocyte ratio may be associated with the outcome in patients with prostate cancer 155
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. 153
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 152
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 152
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 149
Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target 149
A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer. 147
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management 147
A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 147
Panitumumab for the treatment of metastatic colorectal cancer: A review 144
CANCER STEM CELL GENETIC PROFILE AS PREDICTOR OF RELAPSE IN RADICALLY RESECTED COLORECTAL CANCER 143
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. 142
Angiogenetic pathway as a therapeutic target in renal cell carcinoma. 142
Translational challenges from the 2014 Gastrointestinal Cancers Symposium: Toward a true tailored therapy through effective research 142
Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment. 142
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 140
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? 139
Trattamento del carcinoma del pancreas. Attualità e prospettive 139
New target therapies in advanced pancreatic cancer. 138
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. 138
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 138
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 138
Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. 137
Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. 137
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy 136
c-erbB-2 and common prognostic factors in breast cancer patients. 135
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 135
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. 134
The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer 134
Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients 134
Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity. 133
Progress of molecular targeted therapies for advanced renal cell carcinoma. 133
Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 132
A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. 131
Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer 131
Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. 130
A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 128
Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. 128
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 127
A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. 127
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 127
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. 126
Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer 126
A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 125
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. 125
Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 123
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 123
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 123
Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. 123
The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for advanced renal cell carcinoma patients receiving first-line sunitinib 123
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 122
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management 122
Transient sunitinib resistance in gastrointestinal stromal tumors. 122
Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes. 122
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. 120
A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. 120
5-Fluorouracil, leucovorin and interferon alpha 2b in advanced pancreatic cancer: a pilot study. 120
Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. 119
A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. 118
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 118
Palliative treatment 117
Cancer of pancreas. 116
Locoregional treatments of unresectable liver metastases from colorectal cancer. 116
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors 116
Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas. 115
Escalating dose of tegafur combined with oral etoposide in metastatic gastric carcinoma. 115
Recombinant human erythropoietin in chemotherapy-associated anemia. 114
Pain and its treatment in hospitalized patients with metastatic cancer. 114
P-CHOP: cisplatin (P) added to the standard CHOP regimen as first-line treatment for aggressive non-Hodgkin lymphoma: a single-institution phase II study. 113
A randomized, double blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel. 113
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. 113
Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: It is not about the destination, it is about the journey 112
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. 111
Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. 110
Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. 110
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 110
Role of STAT3 pathway in genitourinary tumors 109
The challenge of targeted therapies for gastric cancer patients: The beginning of a long journey 108
Weekly gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase II study 107
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. 107
Totale 15.872
Salva come PNG Salva come JPEG
Categoria #
all - tutte 137.971
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 137.971
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021884 0 0 0 0 0 0 0 0 0 316 374 194
2021/20221.931 113 522 16 69 19 147 71 128 131 207 128 380
2022/20232.713 308 301 215 168 191 322 3 123 837 13 181 51
2023/20241.733 327 31 73 351 320 324 35 34 0 27 15 196
2024/20253.893 386 340 189 27 131 55 337 140 1.099 420 352 417
2025/202612.434 567 1.198 1.884 1.651 1.012 747 1.699 1.175 1.657 844 0 0
Totale 31.101